{"id":50724,"date":"2022-11-10T18:02:23","date_gmt":"2022-11-10T17:02:23","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/her2dx-recognized-by-time-as-one-of-the-best-inventions-of-2022\/"},"modified":"2022-11-10T18:02:23","modified_gmt":"2022-11-10T17:02:23","slug":"her2dx-recognized-by-time-as-one-of-the-best-inventions-of-2022","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/her2dx-recognized-by-time-as-one-of-the-best-inventions-of-2022\/","title":{"rendered":"HER2DX\u00ae Recognized by TIME as One of the Best Inventions of 2022"},"content":{"rendered":"<div>\n<ul class=\"bwlistdisc\">\n<li>\n<b>The publication bestows the recognition on inventions that tackle urgent issues in a creative manner.<\/b>\n<\/li>\n<li>\n<b>HER2DX<sup>\u00ae<\/sup> was highlighted in Times \u201c<i>Medical Care<\/i>\u201d category, which publicizes inventions that are successfully implemented in medical practice.<\/b>\n<\/li>\n<li>\n<b>HER2DX<sup>\u00ae\ufe0f<\/sup> is the first genomic test in the world specialized in HER2+ breast cancer and has been marketed by REVEAL GENOMICS<sup>\u00ae<\/sup> since January 2022.<\/b>\n<\/li>\n<\/ul>\n<p>BARCELONA, Spain&#8211;(BUSINESS WIRE)&#8211;<a href=\"https:\/\/twitter.com\/hashtag\/breastcancer?src=hash\" target=\"_blank\" rel=\"noopener\">#breastcancer<\/a>&#8211;REVEAL GENOMICS, S.L., a biotechnology start-up seeking to revolutionize precision oncology through biomarker innovation, has announced that HER2DX<sup>\u00ae<\/sup> has been included as one of <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftime.com%2Fbest-inventions-2022%2F&amp;esheet=52966383&amp;newsitemid=20221110005713&amp;lan=en-US&amp;anchor=TIME%26%238217%3Bs+%26%238220%3BBest+Inventions+of+2022&amp;index=1&amp;md5=362d66e9fb55853f3fea2bea1f5787b9\" rel=\"nofollow noopener\" shape=\"rect\">TIME\u2019s \u201cBest Inventions of 2022<\/a>\u201d.\n<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20221110005713\/en\/1633285\/5\/Her2dx_logo_Color.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20221110005713\/en\/1633285\/21\/Her2dx_logo_Color.jpg\"><\/a><\/p>\n<p>\nThe list, drawn up yearly and published today, includes new technologies that the publication considers \u201cmake the world better, smarter or even a bit more fun\u201d.\n<\/p>\n<p>\nHER2DX<sup>\u00ae<\/sup> has been recognized as one of the top inventions in the <b>\u201c<i>Medical Care<\/i>\u201d<\/b> category, which highlights cutting-edge innovations that are successfully incorporated into clinical practice and provide patients with good outcomes.\n<\/p>\n<p>\nRegarding HER2DX<sup>\u00ae<\/sup>, the publication said: \u201c<i>The test supports better outcomes for early-stage patients, but it could also lead to more personalized approaches for late-stage breast cancers.\u201d<\/i>\n<\/p>\n<p>\n<i>\u201cThis recognition endorses<\/i><i> our key product and motivates us to continue working towards our vision of the future of precision oncology,\u201d<\/i> says <b>Dr Patricia Villagrasa, Co-founder and CEO of REVEAL GENOMICS<sup>\u00ae<\/sup><\/b>.<i> \u201cWe founded REVEAL GENOMICS<sup>\u00ae<\/sup> with the intention of creating novel, therapeutically useful solutions, and HER2DX<\/i><sup>\u00ae<\/sup><i> is evidence of our potential. The immediate goal of REVEAL GENOMICS\u00ae is to ensure that HER2DX<\/i><sup>\u00ae<\/sup><i> is globally available and reaches all HER2+ breast cancer patients.&#8221;<\/i>\n<\/p>\n<p>\n<b>Co-founder and CSO Dr Aleix Prat<\/b> adds: \u201c<i>It is a huge satisfaction for all on the team to get this endorsement. HER2+ breast cancer affects 400.000 women every year. Prior to HER2DX<\/i><sup>\u00ae<\/sup><i>, we lacked a tool to assist doctors and patients in making crucial therapy decisions. As a result, many patients were experiencing over- or under-treatment. This is why we have developed HER2D<\/i><sup>\u00ae<\/sup><i>X, the first test to help optimize treatment for these types of patients.<\/i>&#8221;\n<\/p>\n<p>\n<b>The best inventions of the year, every year in TIME<\/b>\n<\/p>\n<p>\nThis year\u2019s edition of the awards highlights inventions that made a big impact between November 2021 and September 2022, including HER2DX<sup>\u00ae<\/sup>, which was brought to market in the year.\n<\/p>\n<p>\nTo compile the list, TIME solicited nominations from TIME\u2019s editors and correspondents around the world, and through an online application process, paying special attention to growing fields\u2014such as the electric vehicle industry, green energy, and the metaverse. TIME then evaluated each contender on a number of key factors, including originality, efficacy, ambition, and impact.\n<\/p>\n<p>\nThe full list of winners is published both printed and online &#8211; TIME has a worldwide readership of over 100 million- as well as on social media, including Twitter, where they have 18 million followers, Facebook (13 million fans) and Instagram (11 million followers), together estimated to generate 650 million impressions in the media around the world.\n<\/p>\n<p>\n<b>About the HER2DX<sup>\u00ae<\/sup> test<\/b>\n<\/p>\n<p>\nHER2DX<b><sup>\u00ae<\/sup><\/b> is the world\u2019s first diagnostic test formulated specifically for HER2+ breast cancer. Marketed by REVEAL GENOMICS<b><sup>\u00ae<\/sup><\/b> since January 2022, the HER2DX<sup>\u00ae<\/sup> is a standardized 27-gene expression test for patients with early-stage HER2+ breast cancer.\n<\/p>\n<p>\nHER2DX<sup>\u00ae\ufe0f<\/sup> is a prognostic, predictive assay based on clinical and genomic data. The test integrates clinical information (i.e., tumor size and nodal status) with biological information tracking immune response, luminal differentiation, tumor cell proliferation, and expression of the HER2 17q12-21 chromosomal amplicon, including the ERBB2 gene.\n<\/p>\n<p>\nHER2DX<b><sup>\u00ae<\/sup><\/b> predicts:\n<\/p>\n<ul class=\"bwlistdisc\">\n<li>\n<b>Risk of relapse score <\/b>(high vs. low): the risk of recurrence in patients with newly diagnosed HER2+ breast cancer.\n<\/li>\n<li>\n<b>pCR likelihood score <\/b>(high vs. medium vs. low): the likelihood of a patient to respond to anti-HER2-based treatment before surgery.\n<\/li>\n<li>\n<b>ERBB2 score <\/b>(high vs. medium vs. low): the quantitative expression of ERBB2 mRNA across HER2-negative, HER2-low and HER2+ breast cancer.\n<\/li>\n<\/ul>\n<p>\n<b>About REVEAL GENOMICS<\/b><sup>\u00ae\ufe0f<\/sup>\n<\/p>\n<p>\nREVEAL GENOMICS, S.L. is a biotechnology start-up seeking to change the way biomarkers are used in oncology. It is focused on developing innovative diagnostic tools to define the best therapeutic options for patients with cancer. The company uses pioneering techniques, sophisticated computer applications, and machine learning to reveal new cancer research data.\n<\/p>\n<p>\nREVEAL GENOMICS, S.L. is a spin-off of Hospital Cl\u00ednic of Barcelona, IDIBAPS, University of Barcelona (U.B.), and Vall d\u2019Hebr\u00f3n Institute of Oncology (VHIO).\n<\/p>\n<p>\nREVEAL GENOMICS<sup>\u00ae<\/sup> and HER2DX<sup>\u00ae<\/sup>\u2002are registered trademarks of REVEAL GENOMICS, S.L.\n<\/p>\n<p>\nWeb: <span class=\"bwuline\"><b><a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.reveal-genomics.com&amp;esheet=52966383&amp;newsitemid=20221110005713&amp;lan=en-US&amp;anchor=www.reveal-genomics.com&amp;index=2&amp;md5=b24b564f88e42b4b899b367194168732\" rel=\"nofollow noopener\" shape=\"rect\">www.reveal-genomics.com<\/a><\/b><\/span>.<b> <\/b>Twitter: <b>@revealgenomics<\/b>\n<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\n<b>Further information: <\/b>Adriana Herrera, <span class=\"bwuline\"><a target=\"_blank\" href=\"m&#97;&#x69;&#x6c;&#x74;o&#58;&#97;&#x68;&#x65;r&#114;&#101;&#x72;&#x61;&#64;r&#101;&#x76;&#x65;&#x61;l&#45;&#x67;&#x65;&#x6e;o&#109;&#105;&#x63;&#x73;&#46;&#99;&#111;&#x6d;\" rel=\"nofollow noopener\" shape=\"rect\">&#x61;&#x68;&#x65;&#x72;&#114;&#101;&#114;&#97;&#64;re&#x76;&#x65;&#x61;&#x6c;&#x2d;&#103;&#101;&#110;omi&#x63;&#x73;&#x2e;&#x63;&#x6f;&#109;<\/a><\/span> <b>+34 645 042 889<\/b>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>The publication bestows the recognition on inventions that tackle urgent issues in a creative manner. HER2DX\u00ae was highlighted in Times \u201cMedical Care\u201d category, which publicizes inventions that are successfully implemented in medical practice. HER2DX\u00ae\ufe0f is the first genomic test in the world specialized in HER2+ breast cancer and has been marketed by REVEAL GENOMICS\u00ae since &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/her2dx-recognized-by-time-as-one-of-the-best-inventions-of-2022\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-50724","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>HER2DX\u00ae Recognized by TIME as One of the Best Inventions of 2022 - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/her2dx-recognized-by-time-as-one-of-the-best-inventions-of-2022\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"HER2DX\u00ae Recognized by TIME as One of the Best Inventions of 2022 - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"The publication bestows the recognition on inventions that tackle urgent issues in a creative manner. HER2DX\u00ae was highlighted in Times \u201cMedical Care\u201d category, which publicizes inventions that are successfully implemented in medical practice. HER2DX\u00ae\ufe0f is the first genomic test in the world specialized in HER2+ breast cancer and has been marketed by REVEAL GENOMICS\u00ae since ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/her2dx-recognized-by-time-as-one-of-the-best-inventions-of-2022\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-11-10T17:02:23+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20221110005713\/en\/1633285\/21\/Her2dx_logo_Color.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/her2dx-recognized-by-time-as-one-of-the-best-inventions-of-2022\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/her2dx-recognized-by-time-as-one-of-the-best-inventions-of-2022\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"HER2DX\u00ae Recognized by TIME as One of the Best Inventions of 2022\",\"datePublished\":\"2022-11-10T17:02:23+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/her2dx-recognized-by-time-as-one-of-the-best-inventions-of-2022\\\/\"},\"wordCount\":757,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/her2dx-recognized-by-time-as-one-of-the-best-inventions-of-2022\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221110005713\\\/en\\\/1633285\\\/21\\\/Her2dx_logo_Color.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/her2dx-recognized-by-time-as-one-of-the-best-inventions-of-2022\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/her2dx-recognized-by-time-as-one-of-the-best-inventions-of-2022\\\/\",\"name\":\"HER2DX\u00ae Recognized by TIME as One of the Best Inventions of 2022 - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/her2dx-recognized-by-time-as-one-of-the-best-inventions-of-2022\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/her2dx-recognized-by-time-as-one-of-the-best-inventions-of-2022\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221110005713\\\/en\\\/1633285\\\/21\\\/Her2dx_logo_Color.jpg\",\"datePublished\":\"2022-11-10T17:02:23+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/her2dx-recognized-by-time-as-one-of-the-best-inventions-of-2022\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/her2dx-recognized-by-time-as-one-of-the-best-inventions-of-2022\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/her2dx-recognized-by-time-as-one-of-the-best-inventions-of-2022\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221110005713\\\/en\\\/1633285\\\/21\\\/Her2dx_logo_Color.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221110005713\\\/en\\\/1633285\\\/21\\\/Her2dx_logo_Color.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/her2dx-recognized-by-time-as-one-of-the-best-inventions-of-2022\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"HER2DX\u00ae Recognized by TIME as One of the Best Inventions of 2022\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"HER2DX\u00ae Recognized by TIME as One of the Best Inventions of 2022 - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/her2dx-recognized-by-time-as-one-of-the-best-inventions-of-2022\/","og_locale":"en_US","og_type":"article","og_title":"HER2DX\u00ae Recognized by TIME as One of the Best Inventions of 2022 - Pharma Trend","og_description":"The publication bestows the recognition on inventions that tackle urgent issues in a creative manner. HER2DX\u00ae was highlighted in Times \u201cMedical Care\u201d category, which publicizes inventions that are successfully implemented in medical practice. HER2DX\u00ae\ufe0f is the first genomic test in the world specialized in HER2+ breast cancer and has been marketed by REVEAL GENOMICS\u00ae since ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/her2dx-recognized-by-time-as-one-of-the-best-inventions-of-2022\/","og_site_name":"Pharma Trend","article_published_time":"2022-11-10T17:02:23+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20221110005713\/en\/1633285\/21\/Her2dx_logo_Color.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/her2dx-recognized-by-time-as-one-of-the-best-inventions-of-2022\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/her2dx-recognized-by-time-as-one-of-the-best-inventions-of-2022\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"HER2DX\u00ae Recognized by TIME as One of the Best Inventions of 2022","datePublished":"2022-11-10T17:02:23+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/her2dx-recognized-by-time-as-one-of-the-best-inventions-of-2022\/"},"wordCount":757,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/her2dx-recognized-by-time-as-one-of-the-best-inventions-of-2022\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221110005713\/en\/1633285\/21\/Her2dx_logo_Color.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/her2dx-recognized-by-time-as-one-of-the-best-inventions-of-2022\/","url":"https:\/\/pharma-trend.com\/en\/her2dx-recognized-by-time-as-one-of-the-best-inventions-of-2022\/","name":"HER2DX\u00ae Recognized by TIME as One of the Best Inventions of 2022 - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/her2dx-recognized-by-time-as-one-of-the-best-inventions-of-2022\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/her2dx-recognized-by-time-as-one-of-the-best-inventions-of-2022\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221110005713\/en\/1633285\/21\/Her2dx_logo_Color.jpg","datePublished":"2022-11-10T17:02:23+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/her2dx-recognized-by-time-as-one-of-the-best-inventions-of-2022\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/her2dx-recognized-by-time-as-one-of-the-best-inventions-of-2022\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/her2dx-recognized-by-time-as-one-of-the-best-inventions-of-2022\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20221110005713\/en\/1633285\/21\/Her2dx_logo_Color.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20221110005713\/en\/1633285\/21\/Her2dx_logo_Color.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/her2dx-recognized-by-time-as-one-of-the-best-inventions-of-2022\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"HER2DX\u00ae Recognized by TIME as One of the Best Inventions of 2022"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/50724","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=50724"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/50724\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=50724"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=50724"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=50724"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}